Oryzon Genomics
Develops diagnostic and therapeutic tools.
Launch date
Employees
Market cap
€120m
Enterprise valuation
€123m (Public information from Sep 2024)
Share price
€1.874 ORY.MC
Company register number A62291919
Cornellà de Llobregat Catalonia (HQ)
Financials
Estimates*
EUR | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|---|---|---|
Revenues | 6.0m | - | - | - | - | 2.1m | 7.9m |
% growth | - | - | - | - | - | - | 269 % |
EBITDA | (4.1m) | (5.1m) | (7.4m) | (5.1m) | (4.3m) | (4.3m) | 4.7m |
% EBITDA margin | (68 %) | - | - | - | - | (201 %) | 59 % |
Profit | (4.1m) | (4.2m) | (5.3m) | (4.2m) | (3.4m) | (3.6m) | (<1m) |
% profit margin | (69 %) | - | - | - | - | (170 %) | (10 %) |
EV / revenue | 17.4x | - | - | - | - | 59.2x | 15.1x |
EV / EBITDA | -25.6x | -36.0x | -19.1x | -26.5x | -28.0x | -29.4x | 25.5x |
Source: Dealroom estimates
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
N/A | Spinout | ||
€1.1m | Series A | ||
N/A | N/A | - | |
€11.0m | Series B | ||
$300k | Grant | ||
€500k | Grant | ||
N/A | €1.1m | Grant | |
$270k | Grant | ||
€920k | Grant | ||
N/A | €17.0m | Series C | |
N/A | N/A Valuation: $96.5m | IPO | |
N/A | €10.5m | Post IPO Debt | |
N/A | €5.3m | Post IPO Debt | |
N/A | $800k | Grant | |
N/A | €18.0m | Post IPO Equity | |
N/A | €13.0m | Post IPO Equity | |
$1.5m | Grant | ||
N/A | €20.0m | Post IPO Equity | |
N/A | €20.0m | Post IPO Equity | |
* | N/A | €20.0m | Post IPO Convertible |
* | N/A | €400k | Grant |
* | €45.0m | Post IPO Convertible | |
Total Funding | €34.6m |
Recent News about Oryzon Genomics
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments by Oryzon Genomics
EditACQUISITION by Oryzon Genomics Mar 2009